DarioHealth (NASDAQ:DRIO) Share Price Crosses Below 200-Day Moving Average – What’s Next?

DarioHealth Corp. (NASDAQ:DRIO)’s share price passed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $12.09 and traded as low as $11.77. DarioHealth shares last traded at $11.84, with a volume of 4,038 shares traded.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on DRIO shares. Stifel Nicolaus set a $16.00 target price on shares of DarioHealth in a report on Friday, November 14th. Weiss Ratings reiterated a “sell (d-)” rating on shares of DarioHealth in a research report on Monday, December 29th. Cowen restated a “hold” rating on shares of DarioHealth in a research report on Friday, November 14th. Finally, Wall Street Zen cut DarioHealth from a “hold” rating to a “sell” rating in a report on Saturday, January 3rd. Two equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, DarioHealth has a consensus rating of “Hold” and a consensus price target of $32.00.

DarioHealth Stock Up 0.7%

The company has a debt-to-equity ratio of 0.41, a current ratio of 4.55 and a quick ratio of 4.02. The business’s 50 day moving average price is $11.95 and its 200 day moving average price is $12.09. The firm has a market cap of $80.04 million, a PE ratio of -1.06 and a beta of 1.05.

Hedge Funds Weigh In On DarioHealth

A hedge fund recently raised its stake in DarioHealth stock. XTX Topco Ltd lifted its position in DarioHealth Corp. (NASDAQ:DRIO) by 229.0% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 62,511 shares of the company’s stock after acquiring an additional 43,513 shares during the period. XTX Topco Ltd owned 0.14% of DarioHealth worth $42,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 33.39% of the stock is currently owned by institutional investors and hedge funds.

DarioHealth Company Profile

DarioHealth (NASDAQ:DRIO) is a digital health company specializing in chronic disease management through a smartphone-based care platform. Its core solution combines connected devices—such as glucose meters, blood pressure monitors and smart scales—with real-time data analytics and personalized coaching. The platform is designed to support individuals living with diabetes, hypertension, weight management challenges and other cardiometabolic conditions, offering continuous monitoring, tailored insights and behavioral nudges aimed at improving clinical outcomes.

The Dario platform integrates artificial intelligence and machine learning to deliver personalized guidance and education.